Abstract | BACKGROUND: METHODS: Twenty-two patients aged 24 to 60 years with recurrent AO were treated. All patients had previously been treated with surgery, radiotherapy, adjuvant chemotherapy ( temozolomide, 17; carmustine wafers, 4; carmustine, 1), and 1 salvage regimen ( procarbazine, lomustine, and vincristine, 15; temozolomide, 6; carmustine wafers, 1). Eleven patients underwent repeat surgery. Patients were treated at second recurrence with bevacizumab, once every 2 weeks, defined as a single cycle. Neurological evaluation was performed every 2 weeks, and neuroradiographic assessment was made after the initial 2 cycles of bevacizumab and subsequently after every 4 cycles of bevacizumab. RESULTS: A total of 391 cycles of bevacizumab (median, 14.5 cycles; range, 2-39 cycles) were administered. Bevacizumab-related toxicity included fatigue (14 patients; 4 grade 3), leukopenia (9; 1 grade 3), anemia (5; 0 grade 3), hypertension (5; 1 grade 3), deep vein thrombosis (4; 1 grade 3), and wound dehiscence (2; 1 grade 3). Fifteen (68%) patients demonstrated a partial radiographic response, 1 (5.0%) demonstrated stable disease, and 6 (27%) demonstrated progressive disease after 2 cycles of bevacizumab. Time to tumor progression ranged from 1 to 18 months (median, 6.75 months). Survival ranged from 3 to 19 months (median, 8.5 months). Six-month and 12-month PFS were 68% and 23%, respectively. CONCLUSIONS:
Bevacizumab demonstrated efficacy and acceptable toxicity in this cohort of adults with recurrent 1p19q codeleted alkylator-refractory AO.
|
Authors | Marc C Chamberlain, Sandra Johnston |
Journal | Cancer
(Cancer)
Vol. 115
Issue 8
Pg. 1734-43
(Apr 15 2009)
ISSN: 0008-543X [Print] United States |
PMID | 19197992
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Alkylating
- Bevacizumab
|
Topics |
- Adult
- Angiogenesis Inhibitors
(therapeutic use)
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Alkylating
(therapeutic use)
- Astrocytoma
(drug therapy)
- Bevacizumab
- Brain Neoplasms
(drug therapy)
- Chromosomes, Human, Pair 1
- Disease-Free Survival
- Drug Resistance, Neoplasm
- Female
- Humans
- Male
- Middle Aged
- Oligodendroglioma
(drug therapy, genetics)
- Retrospective Studies
- Survival Analysis
|